Market accessOfficial

Dutch inspectorate publishes report on July 2026 inspection of Maddox Pharma Swiss in Leiden

🇳🇱 IGJ · Thu 12 Nov 2026

The IGJ has released a supervisory report on Maddox Pharma Swiss BV, but the available description does not state any findings or the severity of any deficiencies.

The Dutch Health and Youth Care Inspectorate (IGJ) has published a report following a supervisory inspection visit to Maddox Pharma Swiss BV in Leiden. The visit took place in July 2026, and the document was listed on 12 November 2026.

According to the summary on file, the report sets out the inspectorate's assessment and any improvement measures it requires. The material available to VigiEye, however, does not describe what inspectors found, so the nature and seriousness of any deficiencies cannot be established.

The source entry itself is a bare listing under the IGJ's supervisory documents section, with no further detail on the scope of the inspection, the activities covered or the company's response. Readers will need to consult the full report on the IGJ website for substantive information.

As general context, inspectorate reports of this kind typically record an authority's assessment of a company's compliance with applicable requirements and may list actions the company is expected to take. Whether that applies in this case is not stated in the available material.

What it means for your team

  • Quality and compliance teams with links to Maddox Pharma Swiss BV should read the full IGJ report directly, as no findings are summarised in the listing.
  • No conclusions about the company's compliance status, or any impact on supply or licences, can be drawn from the information currently available.
  • Regulatory intelligence teams may wish to track the IGJ supervisory documents page for follow-up publications relating to this inspection.

Official source: IGJ ↗

Article written by VigiEye from the official source (IGJ). AI-assisted; check the source before acting.

More Market access All →